The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isIn phase 3 as of 2025.
- What to watchSevere upper abdominal pain that radiates to the back.
How Amycretin works
Single molecule hitting both amylin and GLP-1 receptors — additive appetite suppression via different brain circuits; oral and injectable forms.
Amycretin is one molecule that activates the GLP-1 receptor and the amylin receptor, and the published preclinical work says it activates a third one that nobody mentions. In cell-based systems it activated human, mouse and rat GLP-1, amylin AND calcitonin receptors Kuhre 2025.
There is no such gene as ‘the amylin receptor’. An amylin receptor is the calcitonin receptor (CTR) with a receptor-activity-modifying protein bolted onto it: CTR plus RAMP1 is AMY1, plus RAMP2 is AMY2, plus RAMP3 is AMY3. The same seven-transmembrane protein, three different accessory subunits, four different pharmacologies.
- Injectable
Where to get Amycretin
When a vetted partner does, the link and code go here.
Research on Amycretin6 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Phase 1/2 human (~10-13% in 12 wks).
Human clinical evidence
In phase 3 as of 2025. Novo Nordisk's single-molecule GLP-1 and amylin co-agonist. Early phase 1/2 results generated unusual attention: the subcutaneous form reported around 22% weight loss at 36 weeks, and an oral form showed roughly 13% at 12 weeks.
These are early, small. Phase 1 weight numbers have repeatedly failed to hold at phase 3 scale across this entire field, so the figure to watch is the phase 3 readout, not the headline.
Correlative data
No real-world use at all. Trial reports describe class-typical GI effects.
How the mechanism reads
One molecule hitting two receptors — GLP-1 and the amylin receptor — rather than co-formulating two drugs as CagriSema does.
MechanisticAmylin and GLP-1 suppress appetite through genuinely separate pathways: GLP-1 acts largely on hypothalamic and hindbrain circuits, amylin on the area postrema. Hitting both is additive rather than redundant, which is the mechanistic case for the larger effect size.
MechanisticA single molecule also means one pharmacokinetic profile to manage instead of two, which is a real formulation advantage if the ratio is right.
Mechanistic
Sources
- Gasiorek A, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. The Lancet 2025 · PMID 40550229
- Dahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet 2025 · PMID 40550231
- Kuhre RE, et al. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine 2025 · PMID 40706446
- Cao J, et al. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature Communications 2025 · PMID 40204768
- Gu YM, et al. Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica 2025 · PMID 40847076
- Awida Z, et al. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International Journal of Molecular Sciences 2021 · PMID 35008482
Amycretin safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Medullary thyroid cancer or MEN2 in you or a relative, the GLP-1 receptor class warning.
- Past pancreatitis.
- Type 1 diabetes, insulin or sulfonylurea use, because intake falls and low blood sugar becomes likely.
- Gastroparesis or severe gut motility disease.
- Pregnancy or planning one soon, as appetite suppression cuts nutrient supply.
What’s expected
- Reduced appetite and early fullness from combined GLP-1 and amylin signaling.
- Nausea, which drove many dropouts in the subcutaneous study.
- Constipation or loose stool as gastric emptying slows.
Watch for
- Severe upper abdominal pain that radiates to the back.
- Repeated vomiting that leaves you dehydrated.
- A neck lump, hoarseness or trouble swallowing.
Labs that tell you it’s working
- HbA1c: the efficacy marker for any incretin-based agent.
- Lipase: pancreatic enzyme if abdominal pain appears.
- Comprehensive Metabolic Panel: kidney function and electrolytes during poor intake or vomiting.
- Insulin (Fasting): shows insulin sensitivity improving as weight falls.
Unimolecular GLP-1 and amylin receptor co-agonist: additive satiety through two brainstem and hypothalamic routes plus slowed gastric emptying. PMID 40550229 PMID 40550231
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Amycretin FAQ4 common questions
- Is Amycretin approved for human use?
- No. Amycretin is a research compound.
- What is Amycretin researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- HbA1c; Lipase; Comprehensive Metabolic Panel; Insulin: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Amycretin: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



